vs
Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $158.6M, roughly 1.9× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 22.1%, a 49.1% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 710.6%).
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
EBC vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $158.6M |
| Net Profit | $65.3M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | — | 70.2% |
| Net Margin | 22.1% | 71.2% |
| Revenue YoY | 710.6% | 3661.1% |
| Net Profit YoY | -34.4% | 528.0% |
| EPS (diluted) | $0.29 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.9M | — | ||
| Q4 25 | $37.5M | — | ||
| Q3 25 | $241.5M | — | ||
| Q2 25 | $244.9M | — | ||
| Q1 25 | $31.1M | $158.6M | ||
| Q4 24 | $216.5M | $22.6M | ||
| Q3 24 | $203.4M | — | ||
| Q2 24 | $154.0M | — |
| Q1 26 | $65.3M | — | ||
| Q4 25 | $99.5M | — | ||
| Q3 25 | $106.1M | — | ||
| Q2 25 | $100.2M | — | ||
| Q1 25 | $-217.7M | $112.9M | ||
| Q4 24 | $60.8M | $-10.5M | ||
| Q3 24 | $-6.2M | — | ||
| Q2 24 | $26.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 38.9% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | -590.9% | 70.2% | ||
| Q4 24 | 33.3% | -60.4% | ||
| Q3 24 | -1.6% | — | ||
| Q2 24 | 24.7% | — |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 265.6% | — | ||
| Q3 25 | 44.0% | — | ||
| Q2 25 | 40.9% | — | ||
| Q1 25 | -699.2% | 71.2% | ||
| Q4 24 | 28.1% | -46.4% | ||
| Q3 24 | -3.0% | — | ||
| Q2 24 | 17.1% | — |
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.48 | — | ||
| Q3 25 | $0.53 | — | ||
| Q2 25 | $0.50 | — | ||
| Q1 25 | $-1.08 | $1.90 | ||
| Q4 24 | $0.29 | $-0.15 | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $551.7M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3B | $350.1M |
| Total Assets | $30.6B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $551.7M | — | ||
| Q4 25 | $507.6M | — | ||
| Q3 25 | $703.4M | — | ||
| Q2 25 | $948.3M | — | ||
| Q1 25 | $609.0M | $274.8M | ||
| Q4 24 | $1.9B | $128.0M | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $3.6B | $350.1M | ||
| Q4 24 | $3.6B | $229.0M | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.0B | — |
| Q1 26 | $30.6B | — | ||
| Q4 25 | $30.6B | — | ||
| Q3 25 | $25.5B | — | ||
| Q2 25 | $25.5B | — | ||
| Q1 25 | $25.0B | $406.9M | ||
| Q4 24 | $25.6B | $271.6M | ||
| Q3 24 | $25.5B | — | ||
| Q2 24 | $21.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $432.4M | — | ||
| Q3 25 | $157.1M | — | ||
| Q2 25 | $123.9M | — | ||
| Q1 25 | $47.3M | $131.8M | ||
| Q4 24 | $283.8M | $-23.2M | ||
| Q3 24 | $108.3M | — | ||
| Q2 24 | $54.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.35× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | 4.67× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
